suggested that similar haemodynamic changes may occur after frusemide and glyceryl trinitrate in patients with acute myocardial infarction. The clinical observation of Wilkins, 8 and Hollander et al.9 that administration of diuretic agents may be associated with amelioration of anginal pain, have prompted us to study the possible role of frusemide in patients with typical exercise-induced angina pectoris. Spontaneous changes in the course of coronary artery disease may obscure the effects of any drug intervention after sustained oral treatment in patients with angina pectoris. For this reason, a single dose was used to assess the effectiveness of intravenous and oral frusemide in patients with angina pectoris and documented coronary artery disease not in clinical heart failure. Because 67 of the subjective nature of antianginal response alone, emphasis is placed on the influence of the drug on haemodynamic variables and on ischaemic ST depression.
Subjects and methods
Nineteen patients, aged 42 to 61 years (average 52 years), with coronary artery disease and stable exercise-induced angina pectoris were studied. All patients had either a history of clearly documented myocardial infarction (eight subjects) and/or angiographic proof of more than 70 per cent narrowing in at least one major coronary artery. None had received diuretic drugs, antihypertensive agents, nitrates, or beta blocking agents within 48 hours before examination. The history of anginal pain ranged from six months to eight years and was induced by physical exercise in all patients. None had clinical or radiological evidence of cardiac enlargement or failure, valvular heart disease, or arrhythmias. Informed consent was obtained from each patient.
Thirty minutes before the study period, all subjects exercised at a work load comparable to that of the following main exercise periods. This allowed us to observe the patients' response, the potential occurrence of rhythm disturbances, and also to attenuate the influence of previous exercise per se on the haemodynamics during the study period.
Right heart catheterisation was performed without premedication using Swan 
Results (A) HAEMODYNAMIC STUDIES
The haemodynamic response to intravenous and oral frusemide is presented in Fig. 1 exercise duration as before frusemide, RAMP in the intravenous group decreased from 8-7 ±3-3 mmHg to 3 7 ±2-4 mmHg (p < 0-001) and in the oral group from 9 5 ±3 0 numHg to 5*6 ±4-3 mmHg (p < 0 01).
The decrease in pulmonary artery mean pressure (PAMP) was similar to the PWP reduction after frusemide. The exercise value of PAMP in the intravenous group decreased from 45-2 +9-8 mmHg to 273 ±6-3nmmHg (p<0001), and in the oral group from 40'4 +417 mmHg to 31-4 ±11-3 mmHg (p <005).
Cardiac output at rest after intravenous frusemide fell by 16 per cent (6-3±1t01/min vs. 5-3±0-8 1/min, p<0-001) and after oral frusemide by 15 per cent (617 +0t9 I/min vs. 5-7 ±0-8 1/min, p < 0 01).
The reduction in cardiac output during exercise after frusemide was 7 per cent in the intravenous group (10.1 ±2-0 1/min vs. 94 ± 18 1/min, p < 0 005) and after oral frusemide 10 per cent (10-9 ±2-3 1/min vs. 9-8 ±t1-8 I/min, p < 0-01).
During the control exercise period an increase in the v wave amplitude was observed in the PWP recordings of seven patients during angina, suggesting mitral regurgitation. These alterations disappeared completely after administration of the drug (Fig. 4a, b) .
Heart rate did not change after frusemide, either at rest or during exercise. The average resting heart rate of the 19 patients was 76-3 ±13-4/min during the control period, and 75-9 ±13 9/min after frusemide; the exercise values were 114-7 ±18-9 and 113-9 ± 191/min, respectively. (C) ANGINA PECTORIS During the control study period, all patients experienced mild (n=3), moderate (n=8), or severe (n =8) angina at a mean work load of 51 watt (range 10 to 110 watt). During exercise after frusemide 10 patients were completely free of chest pain at the same exercise duration. Three patients indicated amelioration of chest pain from "severe" to "mild", three patients from "severe" to "moderate", and two patients from "moderate" to "mild". In one patient the complaints were unchanged. Nine of the ten patients who were completely free of complaints continued exercising at the same level of work load for an average of 3-5 minutes (range 1 to 4-5 minutes). The exercise end-point in these patients was a result of angina (three patients) and exhaustion (six patients).
(D) SERUM POTASSIUM Serum potassium levels were obtained the day before and several hours after completion of the study. No significant changes could be found after a single intravenous or oral dose of 40 mg frusemide.
There were no side effects or complications during the studv. 
Discussion
For the purpose of this study it was important not to accept exercise results uncritically. In fact it has been repeatedly shown that the first exercise challenge is usually a learning experience for the patient and that symptoms, pulmonary artery pressures, and other haemodynamic variables may improve during the second exercise period after repeated exercise at the same work load.13 Therefore, repeated exercise must be interpreted with caution when studying the effect of pharmacological intervention on haemodynamics. In order to compensate for this phenomenon, an exercise study after any drug intervention should be made during the third rather than during the second exercise test.14 This was achieved by an exercise test 30 minutes before the study period at a work load comparable to that of the following pre-and postfrusemide studies. The influence of previous exercise per se on the haemodynamic data during the study period is thus avoided.'4
The present study shows that the major and most consistent effect of intravenous and oral frusemide is a prompt reduction in right and left ventricular filling pressures at the same level of exercise in patients with angina pectoris. (that is myocardial systolic wall tension) is a function not only of intraventricular systolic pressure but also of ventricular volume, it may be readily appreciated that a diuretic agent that reduces preload may lower afterload by reducing ventricular volume. Furthermore, the action of frusemide is not exclusively related to its diuretic properties. Rather, the immediate haemodynamic effect of the drug is primarily vascular in origin, since pronounced changes in venous capacitance could be shown, indicating a strong venous pooling effect.6 7 The haemodynamic effects of frusemide are probably secondary to both fluid depletion and increased venous capacitance.
Our haemodynamic data strongly suggest that the "antianginal" effects of frusemide can be attributed to the unloading action of the drug. Fig. 3 shows that a steep rise in left ventricular filling pressure precedes the occurrence of anginal symptoms in most patients. After administration of frusemide the rise in filling pressures is clearly attenuated and the angina end-point delayed relative to the pre-frusemide end-point. On the other hand, angina in the post-frusemide test, though mitigated, occurred at lower filling pressures than during the control study. One patient (case 10) experienced angina at a very low filling pressure even in the pre-frusemide experiment. These latter results indicate that other mechanisms apart from left ventricular filling conditions are involved in the precipitation and termination of angina pectoris in patients with coronary artery disease.
We have plotted the changes in cardiac output against left ventricular filling pressure after frusemide to provide an approximate assessment of reduces cardiac output during exercise. It also reduces systemic arterial pressure, and baroreceptor-mediated increases in heart rate tend to have opposite effects on myocardial oxygen consumption.'1 24 Beta blocking agents tend to increase left ventricular filling pressure during exercise in patients with coronary artery disease, as well as in normal subjects,25-27 and thus may attenuate the beneficial effect on myocardial oxygen demand. In this study, frusemide improved cardiac performance, as evidenced by a shift to the left of the cardiac output/filling pressure relation, but did not induce changes in systemic blood pressure nor changes in heart rate. It appears that the antianginal properties of frusemide are the result of reduced left ventricular volume in systole and diastole. This leads to reduced myocardial wall tension and lower myocardial oxygen requirements. Reduction of wall tension during diastole will allow for improved perfusion of the myocardium, especially of the subendocardial layers of the left ventricle. These effects are suggested as being related to the venodilator capacity of frusemide, which is later supplemented by its diuretic action.
Conclusions from these findings should be restricted to the acute symptomatic and haemodynamic response to 
